Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for ...

Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Stock futures fell again Monday, after the S&P 500 had its worst week in months amid fears about President Donald Trump's tariff policy. Mark Carney won the race to replace Justin Trudeau as Canada's ...

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...

The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...